Xtant Medical (XTNT) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Brett Maas - Managing PartnerSean Browne - President, CEO & DirectorScott Neils - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareRyan Zimmerman - Managing Director & Medical Technology Analyst Operator Good afternoon, everyone, and welcome to the Xtant Medical First Quarter twenty twenty five Financial Results. Please note this conference is being re ...

Xtant Medical (XTNT) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Speaker0 Good afternoon, everyone, and welcome to the Xtant Medical First Quarter twenty twenty five Financial Results. Please note this conference is being recorded. I will now turn the conference over to your host, Brett Maas of Hayden Investor Relations. Brett, the floor is yours. Speaker1 Thank you, operator. Joining me today is Sean Brown, President and Chief Executive Officer and Scott Neals, Chief Financial Officer. Today's call is b ...

Core Insights - Xtant Medical Holdings, Inc. reported a positive net income of $58,000 for Q1 2025, a significant improvement from a net loss of $4.4 million in Q1 2024, indicating a turnaround in financial performance [4][9] - The company achieved an 18% year-over-year revenue growth, reaching $32.9 million, driven by increased sales in orthobiologics and licensing revenue [2][3] - Xtant Medical has raised its revenue guidance for the full year 2025 to between $127 million and $131 million, reflecting an expected growth of 8% to 12% [10] Financial Highlights - Revenue for Q1 2025 was $32.9 million, compared to $27.9 million in Q1 2024, marking an 18% increase [3][9] - Gross margin decreased slightly to 61.5% from 62.1% year-over-year, primarily due to charges for excess and obsolete inventory [3][9] - Operating expenses decreased to $19.2 million in Q1 2025 from $20.8 million in Q1 2024, mainly due to reduced compensation and commission expenses [4][9] Cash Flow and EBITDA - The company generated $1.3 million in operating cash flow in Q1 2025, a turnaround from cash used in operations of $5.8 million in the prior year [2][9] - Non-GAAP adjusted EBITDA for Q1 2025 was $3.0 million, compared to an adjusted EBITDA loss of $1.0 million in Q1 2024 [5][9] Product Development - Xtant Medical launched Trivium™, a next-generation demineralized bone matrix allograft, which is expected to enhance the company's orthobiologics portfolio and drive future growth [2][9] Corporate Developments - The company completed a secondary private sale of existing shares by OrbiMed Advisors LLC, enhancing corporate governance flexibility by terminating the investor rights agreement with OrbiMed [9]